Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (279)	2/11/2003 12:59:56 PM
From: Jibacoa	Respond to of 3722

LGND May be finding support at the 4 level.<g> At a meeting yesterday it was reported that treatment with LGND's ONTAK was able to achieve remission in 5 of 11 patients with acute GVHD, and another 2 patients had a partial remission, for an overall response rate of 64%(seven of 11 patients). Of course back in December at the ASH meeting it was already reported good results of ONTAK on GVHD as well as on CLL and NHL.(ONTAK has already been approved by the FDA since Feb.1999 for treatment of patients with persistent or recurrent CTCL who express the p55 (CD25) component of the IL-2 receptor.) And LGND's Targretin,which also received FDA approval for for the treatment of cutaneous manifestations of CTCL in December 1999 and is on phase III trials as oral treatment for NSCLC and has also shown to be able to "dramatically reduce" <g> the development of ER negative mammary tumors in mice . And GSK has begun human trials of SB-497115 for thrombocytopenia. (There are no approved TPO agents for the treatment or prevention of thrombocytopenia and LGND believes that its small molecule oral drug that mimics TPO with no apparent immunogenic side effects will provide therapy for a major unmet medical need.<g> In view of LGND's good pipeline and its collaboration with important large corporate partners in products with large market indications like osteoporosis, diabetes,CVD, oncology and contraception it seems the R/R is favorable at present levels.<g> siliconinvestor.com siliconinvestor.com Of course LGND shares need to close its Nov.13 down-gap and will look much better if they can close above 7.<g> siliconinvestor.com Bernard

To: Jibacoa who wrote (279)	2/18/2003 4:17:17 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

CRIS Was up 19.86% on volume of 172,750 (more than 2x its daily average) It reported that two independent studies showed that a human protein, called Sonic Hedgehog, restored nerve function after diabetes-induced nerve damage and could be of benefit on other types of nerve damage. The studies were conducted in the labs at the UCL in San Diego and the Univ. of Manchester in the U.K In the 1stQ of 2002, CRIS announced a realignment of its research and development programs and said it was to concentrate its resources on its signaling pathways and stem cell technologies,the Bone Morphogenic Protein (BMP) and the Hedgehog (Hh) family of product candidates. The BMP proteins seem to play a role in the development and repair of bone and kidneys, and also in the repair mechanisms of the brain. The BMP-7 protein appears to inhibit kidney inflammation and also stimulate the production of molecules that promote normal blood flow to the kidney. The Hedgehog Family (Sonic, Desert and Indian)seem to play a key role in the formation, maintenance and repair of a number of tissues, including the nervous system and cartilage, as well as in the control of blood vessel formation. Sonic Hh (SHh) has been shown to regulate blood vessel, central nervous system and hair development; Desert Hh has been shown to affect peripheral nervous system development and function; and Indian Hh has been shown to control the formation and growth of cartilage. SHh has been shown to reduce behavioral impairment and dopaminergic nerve loss in preclinical models of Parkinson's Disease. Previous to today's report,scientists in the U.K.,using rodent models of diabetic neuropathy have shown that SHh restores normal nerve function as measured by nerve conduction velocity. CRIS has small molecule compounds that appear to mimic the effects of SHh and are potential drug candidates for Parkinson's and diabetic neuropathy and have the advantage of been able to be administered orallly.. siliconinvestor.com Bernard